Answers are grounded in this paper and cite their sources.
BACKGROUND: Transurethral resection of bladder tumor (TURBT) using photodynamic diagnosis (PDD) with 5-aminolevulinic acid hydrochloride (5-ALA) to treat non-muscle-invasive bladder cancer (NMIBC) frequently results in hypotension being reported as a serious side effect. After this method had been approved for oral administration 2-8 hours (h) prior to cystoscope insertion in September 2024, no reports thoroughly investigated hypotension occurring with newly approved 5-ALA administration timing. METHODS: We retrospectively compared the systolic blood pressure (SBP) values with the frequency of vasopressors between the 5-ALA exposure time 2-4 h group and that of 4-8 h group. Multivariable logistic regression analyses between them were performed for patients with (1) SBP <80 mmHg using vasopressors, and (2) treatment with vasopressors for >60 min. RESULTS: The final analysis investigated 395 patients who underwent PDD-TURBT. The incidence of hypotension was 57.7% in the 5-ALA exposure time 2-4 h group and 40.4% in that of 4-8 h group (p = 0.002). The mean intraoperative lowest SBP was 78.7 mmHg in the 5-ALA exposure time 2-4 h group and 84.5 mmHg in that of 4-8 h group (p = 0.002). Our multivariate analyses identified risk factors for 5-ALA-induced hypotension. CONCLUSIONS: We showed that the risk factors for 5-ALA-induced hypotension differ depending on the timing of 5-ALA administration, and that the 5-ALA exposure time 4-8 h may reduce the risk compared to that of 2-4 h. Furthermore, it became clear that careful consideration is necessary when using 5-ALA, recognizing the differences in risks in clinical use.
No takes yet. Share an insight, caveat, or question.
Fukuhara et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: